A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant DurvalumabAlone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA N0-1)Non-small Cell Lung Cancer (NeoCOAST)

Project: Research project

Project Details

Description

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA N0-1) Non-small Cell Lung Cancer (NeoCOAST)
StatusActive
Effective start/end date1/23/191/31/24

Funding

  • MedImmune, LLC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.